Westlake Village-based Cynvenio, a developer of cancer diagnostics and biomarker monitoring technology, and cloud-based expert system maker CollabRx have teamed up with a new, web-based cancer decision support application, according to the two. According to the companies, the two have tied Cynvenio's ClearID genomic test with cancer decision support software from CollabRx, which will help breast cancer patients and their physicians understand treatment options. Financial details of the deal were not disclosed. Cynvenio develops a monitoring test for breast cancer survivors at high risk of disease recurrence. Cynvenio is led by Andre de Fusco.
Top NewsTuesday, August 5, 2014
Cynvenio, CollabRx Team On Cancer Therapy Tool